Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 16Carcinoma, Renal Cell 14Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Neoplasms 6Carcinoma, Medullary 6Thyroid Neoplasms 5Melanoma 5Breast Neoplasms 5Ovarian Neoplasms 4Neuroendocrine Tumors 4Carcinoma, Transitional Cell 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Kidney Neoplasms 3Adenocarcinoma, Follicular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Pain 2Osteosarcoma 2Multiple Myeloma 2

Interventions

Sunitinib 3Everolimus 3cabozantinib 2Temozolomide 2sapanisertib 1motesanib diphosphate 1ibrutinib 1ganitumab 1batifiban 1aflibercept 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Oxaliplatin 1Octreotide 1Magnetic Resonance Spectroscopy 1Leucovorin 1Fluorouracil 1Doxorubicin 1Cryotherapy 1Capecitabine 1Bevacizumab 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Adenoma, Islet Cell × cabozantinib × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT01466036 2024-03-05

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
61 enrolled 9 charts
Endocrine

Carcinoid Tumor, Adenoma, Islet Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡